Biotechnology

Neurophet-AriBio to develop 'Next-Gen Platform for Alzheimer's diagnosis'

- Neurophet's brain MRI analysis technology incorporates fluid biomarker data from AriBio's global Phase 3 clinical trial for Alzheimer's disease - Collaborates leveraging Neurophet's medical image analysis technology and AriBio's clinical trial data analysis expertise SEOUL, South Korea, Oct. 1...

2024-10-15 21:00 1263

Bloomage Debuts New Products at CPHI Milan to Reinforce Its Commitment to Innovation

MILAN, Oct. 15, 2024 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, unveiled its Hyatrue® Sterile Sodium Hyaluronate (HA) and showcased its BloomseaN™ Polydeoxyribonucleotide (PDRN) and Polynucleotide (PN) at CPHI Milan. Known to be at "the...

2024-10-15 21:00 793

Prenetics Announces Tencent's US$30 Million Investment in Insighta, Strengthening Strategic Partnership for AI-Driven Early Cancer Detection

HONG KONG, Oct. 15, 2024 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leading health sciences company, today announced thatTencent has made a strategicUS$30 million investment in Insighta, a Hong Kong-based early cancer detection company. This investment values Insighta atUS$200 mill...

2024-10-15 20:50 3638

DBN Group Invites Global Agricultural Biotech Companies to Co-create a Leading Innovation Ecosystem at DBN Phoenix International Innovation Park

BEIJING, Oct. 15, 2024 /PRNewswire/ -- DBN Group , a leading high-tech agricultural enterprise, has opened its Phoenix International Innovation Park for global applications from high-quality agricultural biotech companies. This initiative seeks to establish an ope...

2024-10-15 13:45 1740

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration

* Safety Review Committee (SRC) approves single ascending dose 4mg cohort in Phase 1 trial of PMC-403, preparing for multiple ascending dose 4 mg cohort. * PMC-403 is being explored in broader therapeutic areas, including rare vascular disease systemic capillary leak syndrome (SCLS) and kidney...

2024-10-15 09:51 1265

Illuma, Global Pioneer in HMO Research, Launches Traceability Journey in Switzerland, Unveiling Next-Generation HMO Innovations

VEVEY, Switzerland, Oct. 14, 2024 /PRNewswire/ -- Recently at Nestlé's headquarters inVevey, Switzerland, illuma, a global super premium brand of maternal and infant nutrition under Nestlé, began its "Human Milk Oligosaccharides (HMO) Research Traceability Journey". With a focus on the most rece...

2024-10-14 23:31 1158

Tsingke Shines at Cell & Gene Therapy International 2024

BEIJING and BOSTON, Oct. 14, 2024 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. recently concluded a successful exhibition at CGTI2024 inBoston. This premier event attracted over 3,200 global attendees, including professionals from the top 20 biopharma companies. Tsingke showcased its innovat...

2024-10-14 20:11 1457

US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors, Sponsored by the US National Cancer Institute

TAIPEI and SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that FDA issues Study May Proceed letter for its developing drug Pid...

2024-10-14 19:00 1728

Samsung Biologics launches high-concentration formulation platform to accelerate high-dose drug development

* S-HiConTM is designed to maximize drug delivery and stability through high-concentration formulation * The platform can address challenges associated with viscosity and achieve stable liquid formulation for over 200 mg/mL subcutaneous administration INCHEON, South Korea, Oct. 14, 2024 /PRNe...

2024-10-14 19:00 1612

Novotech Awarded Frost & Sullivan's 2024 Global Company of the Year Award for Its Leadership and Excellence in Biotech CRO Services

Novotech's innovative full-service approach accelerates clinical development with advanced analytics, diverse global patient access, and specialized technology. SAN ANTONIO, Oct. 14, 2024 /PRNewswire/ -- Frost & Sullivan recently conducted an in-depth analysis of the biotech contract research or...

2024-10-14 12:30 1172

21st TAITA Annual Conference Explores Taiwan's AI Era Strategies in the Global Tech Supply Chain

TAIPEI, Oct. 13, 2024 /PRNewswire/ -- The upcoming 21st TAITA-SV Annual Conference, scheduled forSaturday, October 19, 2024, at the Hyatt Regency Hotel inSanta Clara, California, will focus on the theme "Taiwan's Strategic Layout in the AI Era." The conference will explore howTaiwan leverages its...

2024-10-14 10:32 1237

Waters New Bioseparations Tools Accelerate and Improve Development of RNA-based Vaccines and Therapies Using LC-MS Analysis

News Summary: * Waters new LC-MS grade reagents, enzymes, and software simplify large molecule RNA analysis to accelerate and improve development of mRNA vaccines, personalized cancer therapies, and innovative drugs for genetic disorders. * Novel digestion enzymes deliver complete RNA sequenc...

2024-10-14 08:00 1589

Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center...

2024-10-13 16:04 2114

Ailux Biologics, a Division of XtalPi, Enters into a License Agreement with Janssen Biotech on Biologics AI Platform

CAMBRIDGE, Mass., Oct. 12, 2024 /PRNewswire/ -- XtalPi, a global leader in AI drug discovery, announced today a license agreement between Ailux Biologics, a division of XtalPi Inc., and Janssen Biotech, Inc.,(Janssen) a Johnson & Johnson company, on one of its proprietary biologics AI platforms. ...

2024-10-12 16:57 4098

Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024

Total revenues increased to US$13.1 million, representing 13.8% year-over-year growth Net income reached US$4.4 million, representing 85.8% year-over-year growth GUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"...

2024-10-11 20:00 4450

GenScript Biotech Advances Sustainable Development with MSCI ESG Rating Upgrade to A

PISCATAWAY, N.J., Oct. 11, 2024 /PRNewswire/ -- GenScript Biotech Corporation has recently been upgraded to an A rating in its Environmental, Social, and Governance (ESG) score by MSCI, a globally recognized rating agency. This upgrade reflects GenScript's unwavering commitment to integrating su...

2024-10-11 17:09 2453

Angel Yeast Contributes USD 43.46 Million to Establish New Subsidiary and Yeast Production Facility in Indonesia

BANDAR LAMPUNG, Indonesia, Oct. 10, 2024 /PRNewswire/ -- Angel Yeast (SH:600298) a global leader in yeast manufacturing, is partnering with Indonesian agricultural company PT.Tunas Baru Lampung Tbk ("TBLA") to set up a subsidiary in Lampung Province and acquire land...

2024-10-10 19:30 5911

Nobel laureate Professor Michael Levitt shares his journey in science with students and staff at XJTLU

SUZHOU, China, Oct. 10, 2024 /PRNewswire/ -- On 8 October, Xi'an Jiaotong- Liverpool University (XJTLU) welcomed Nobel laureate Professor Michael Levitt for an engaging science talk. He delivered the talk, A Wonderful Life in Science, both onsite and to a worldwide online audience. &a...

2024-10-10 11:06 2000

Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Oct. 9, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunolo...

2024-10-10 11:04 1362

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...

2024-10-09 23:37 2647
1 ... 13141516171819 ... 311